U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110064) titled 'QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer' on July 31.
Brief Summary: The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced pancreatic cancer who have not received prior treatment. This study aims to enhance the anti-tumor immune effect through the combination of QL1706+Lenvatinib+AG regimen, thereby improving the prognosis of patients with advanced metastatic pancreatic cancer.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Advance Pancreatic Cancer
Intervention:
DRUG: QL1706+Lenvatinib+AG Regimen...